Curis (NASDAQ:CRIS – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Trading Up 0.3 %
CRIS stock opened at $3.23 on Wednesday. Curis has a 1-year low of $2.86 and a 1-year high of $17.49. The company’s 50 day moving average is $3.44 and its 200 day moving average is $4.42. The stock has a market cap of $27.36 million, a price-to-earnings ratio of -0.41 and a beta of 3.41.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Curis in a research note on Tuesday, December 10th.
Curis Company Profile
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Read More
- Five stocks we like better than Curis
- 3 Fintech Stocks With Good 2021 Prospects
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- Transportation Stocks Investing
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- ESG Stocks, What Investors Should Know
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
